First approved for adults in 2022, the therapy is now cleared for adults and pediatric patients weighing 66 lbs or more with symptomatic obstructive hypertrophic cardiomyopathy.
News|Articles|August 11, 2008
New products bring lice treatment to a head
It has been 22 years since the Food and Drug Administration approved a new prescription drug treatment for head lice, but now several new remedies are on the horizon.
Advertisement
What's in the future
More information on lice and the misconceptions surrounding them can be found under Web Exclusives on
THE AUTHOR is a writer based in New Hampshire.
Advertisement
Related to this article
A claims analysis of 2031 patients aged 10 to 17 years found that nutrition counseling was infrequent and often began months after treatment started.
Availability will vary by state, and a pharmacy professor says cost barriers can keep families from getting vaccinated.
The once daily tablet is expected to reach US patients in October 2026.
The label expansion adds patients 12 years of age and older to the once daily alopecia areata indication.
This episode offers a detailed look into the FDA’s recent PCAC meeting and what the future of peptide compounding could lead to for pharmacy professionals.
A study finds children starting continuous glucose monitoring within a month of diagnosis sustained lower hemoglobin A1C than those who started later.
Eli Lilly’s new indication helps improve medication delivery for adults with type 2 diabetes, reducing annual injections by over 300.
Advertisement
Advertisement